DOCSLIB.ORG

STATUS DS 8 Panel PI-1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
STATUS DS 8 Panel PI-1 References Symbols Key P- 58181-D THC (Δ9-tetrahydrocannabinol) is the primary active ingredient in 1. Tietz, Norbert W. Textbook of Clinical Chemistry. W.B. Saun- cannabinoids (marijuana). When ingested or smoked, it produces ders Company. 1986, p. 1735. euphoric effects. Users experience impairment of short term 2. Hawks RL, Chiang CN, eds. Urine Testing for Drugs of Abuse. DS memory and THC use slows learning. Also, it may cause transient Instructions For Use (Read) episodes of confusion, anxiety, or frank toxic delirium. Long term, National Institute on Drug Abuse (NIDA), Research Monograph THC/OPI/COC/AMP/BZO/BAR/TCA/PCP relatively heavy use may be associated with behavioral disorders. 73; 1986. REF Item Number One-Step Panel Test for Drugs of Abuse The peak effect of smoking THC occurs in 20–30 minutes and the 3. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. duration is 90–120 minutes after one cigarette. Elevated levels of 2nd Ed., Davis, CA: Biomedical Publ.; 1982; p.488. Store At For In Vitro Use Only urinary metabolites are found within hours of exposure and remain 4. Stewart DJ, Inoba T, Ducassen M, and Kalow W. Clin. Pharma- detectable for 3–10 days after smoking. The main metabolite col. Ther. 1979;25: 264–8. excreted in the urine is 11-nor-Δ9-tetrahydrocannabinol-9 Expiration Date Simple One-Step Immunoassay 1 5. Ambre JJ. Anal. Toxicol. 1985;9:241–5. -carboxylic acid. for the Qualitative Detection of Opiates, Cocaine, THC, 6. Blum K. Handbook of Abusable Drugs. 1st ed. New York: Gardner Press, Inc.; 1984. CONT Contents Phencyclidine, Benzodiazepines, Barbiturates, Tricyclic Phencyclidine is an arylcyclohexylamine that is used as a 7. Fairlight Consulting. Antidepressants, Amphetamine, and/or their Metabolites in veterinary anesthetic. It is used illegally as a hallucinogen, and is http://www.fairlite.com/ocd/articles/tricyclic.shtml IFU Instructions For Use Urine commonly referred to as PCP, angel dust, love boat, hog, or killer weed. PCP can produce lethargy, euphoria, ataxia, nystagmus 8. Bickel MH. Poisoning by Tricyclic Antidepressant Drugs. Int. J. and coma. Currently a number of PCP analogues with similar Clinical Pharmacol. 11 (1975) 145-176 (No. 2). PIP Transfer Pipette pharmacological effects are in use as street drugs, including PCE, LifeSign, LLC PHP, TCP, and ketamine. Phencyclidine is readily absorbed when IVD For In Vitro Diagnostic Use smoked or ingested, or even through skin contact. It is Item No. 28010 10 Test Kit metabolized in the liver. Evidence indicates that PCP undergoes oxidative metabolism to at least 2 inactive metabolites, LOT Lot Number Item No. 28025 25 Test Kit 4-phenyl-4-piperidino-cyclohexanol and 1-(1-phenylcyclohexyl)-4-hydroxypiperidine, which are excreted as Manufacturer glucuronide conjugates in the urine. About 10% of the dose is Intended Use excreted in urine as the parent compound, phencyclidine.2,3 MF Manufactured For Benzodiazepines are a class of widely prescribed central nervous Status DS 8 Panel (THC/OPI/COC/AMP/BZO/BAR/TCA/PCP) system (CNS) depressants and include widely used drugs such as EC REP Authorized Representative test is a simple, one-step immunochromatographic assay for the rapid, qualitative detection of opiates, cocaine, THC, phencyclidine, chlordiazepoxide, diazepam, and oxazepam. They have medically benzodiazepines, barbiturates, tricyclic antidepressants, useful properties, including antianxiety, sedative, anticonvulsant, CE Mark amphetamine, and/or their metabolites present in human urine at and hypnotic effects. They are taken orally or sometimes by the cutoff concentration of the drug specified, see Expected Values. injection, and have a low potential for physical or psychological dependence. Benzodiazepines induce drowsiness and muscle Status DS 8Panel (THC/OPI/COC/AMP/BZO/BAR/TCA/PCP) relaxation; however, their use can also result in intoxication, similar test provides only a preliminary analytical result. A more to drunken behavior except without evidence of alcohol use, and specific alternative chemical method must be used in order to the loss of inhibitions. Chronic abuse can result in addiction and obtain a confirmed analytical result. Gas chromatography, tardive dyskinesia (involuntary muscle movements of the face, mass spectrometry (GC/MS) is the preferred confirmatory limbs, and trunk). Overdose can result in coma and possible method. Other chemical confirmatory methods are available. death. Withdrawal syndrome includes anxiety, insomnia, tremors, Clinical consideration and professional judgment should be delirium, and convulsions. The effects of benzodiazepine use last applied to any drug of abuse test result, particularly when 4–8 hours. The different benzodiazepines are absorbed at different preliminary positive results are used.2 rates, and the timing of their psychoactive effects varies with the absorption rate. The drugs are excreted in the urine primarily as Summary and Explanation the parent compounds or as oxazepam glucuronide, an inactive Morphine, codeine, and semisynthetic derivatives of morphine metabolite, (in the case of chlordiazepoxide and diazepam) and are detectable for 1–2 days. Oxazepam may be detectable in the belong to the class of drugs called opiates. An opiate exerts its 2,3 effects on the central nervous system and can produce euphoria, urine for up to 7 days. respiratory depression and coma when it is abused. Morphine is the prototype compound of opiates. Morphine is excreted in the Barbiturates are a group of chemicals derived from barbituric urine as morphine-3-glucuronide, unchanged morphine, and other acid. Classified as hypnotics, they depress the central nervous minor metabolites. Heroin is metabolized to morphine and codeine system. Taken orally in pill or tablet form, they are prescribed for and excreted in the urine with a small amount of unchanged form. many medical conditions, usually for their sedative effect. Abuse Codeine is also excreted as morphine and in the form of of barbiturates can, however, lead not only to impaired motor conjugates. Although some opiate metabolites appear in the feces, 1,2,3 coordination and mental disorder, but also to respiratory collapse, urinary excretion is the primary route of elimination. coma and death. The combination of barbiturates and alcohol is particularly dangerous. Symptoms of barbiturate abuse include Cocaine, derived from the leaves of coca plant, is a potent central drowsiness, slurred speech and irritability. Acute conditions nervous system (CNS) stimulant and a local anesthetic. Cocaine include respiratory collapse and loss of consciousness. Chronic induces euphoria, confidence and a sense of increased energy in conditions include addiction, abstinence and seizures. The effects the user; these psychological effects are accompanied by increased of short-acting barbiturates such as pentobarbital and heart rate, dilation of the pupils, fever,tremors and sweating. secobarbital last 3 to 6 hours. The effects of long-acting Cocaine is used by smoking, intravenous, intranasal or oral barbiturates last 10 to 20 hours. Phenobarbital is an example of administration, and excreted in the urine primarily as long-acting ones. Barbiturates normally remain detectable in urine benzoylecgonine in a short time. Benzoylecgonine has a longer for 4 to 6 days in the case of short-acting ones and up to 30 days Printed in U.S.A. EC REP Manufactured by MF Manufactured for: biological half-life (5–8 hours) than cocaine (0.5–1.5 hours) and can for long-acting ones. Short-acting barbiturates are generally P-58181-D generally be detected for 24–60 hours after cocaine use or excreted as metabolites, while long-acting ones primarily appear 33-7/11/12 MT Promedt Consulting GmbH exposure.3,5 unchanged.2,3 Altenhofstrasse 80 66386 St. Ingbert Princeton BioMeditech Corporation Germany 4242 U.S. Hwy 1, Monmouth Jct. A PBM Group Company +49-68 94-58 10 20 New Jersey 08852, U.S.A. 85 Orchard Road, 1-732-274–1000 www.pbmc.com Skillman, NJ 08558 800-526-2125, 732-246-3366 www.lifesignmed.com 8 1 Tricyclic antidepressants (TCAs) are a type of prescription drug • Status DS 8 Panel(THC/OPI/COC /AMP/BZO/BAR/TCA/PCP) COC AMP intended for clinically depressed patients. Unfortunately, they are device. The test device contains membrane strips and dye Benzoylecgonine 300 D-Amphetamine 1,000 pads: Membrane strips are coated with THC-protein (a Cocaine HCl >100,000 D,L-Amphetamine 1,800 becoming more frequently abused and are now one of the leading L-Amphetamine 37,500 purified bovine protein) conjugate, PCP-protein (a purified Ecgonine HCl >100,000 causes of death by drug overdose in the United States. There are Benzphetamine >100,000 two broad chemical classes of TCAs. The tertiary bovine protein) conjugate, monoclonal , anti-morphine, THC D-Methamphetamine >100,000 amines—amitriptyline, imipramine, trimipramine and anti-benzoylecgonine, anti-barbiturate, and Cannabinol >100,000 p-OH-Methamphetamine >100,000 doxepin—boost serotonin levels and are prescribed for insomnia, anti-amphetamine antibodies, as well as polyclonal 11-hydroxy-Δ9-THC 7,500 Methylenedioxyamphetamine 2,000 irritability and over stimulation. The secondary anti-oxazepam, anti-methadone, and anti-tricyclic 11-nor-Δ8-THC-9-COOH 250 Methlyenedioxymethamphetamine >100,000 amines—nortriptyline, desipramine and protryptiline—enhance antidepressant antibodies. Sheep anti-mouse antibody is 11-nor-Δ9-THC-9-COOH 50 ß-Phenylethylamine 40,000 norepinephrine levels and are prescribed for opposite types of coated for the control
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • (LSD) Test Dip Card (Urine) • Specimen Collection Container % Agreement 98.8% 99
    frozen and stored below -20°C. Frozen specimens should be thawed and mixed before testing. GC/MS. The following results were tabulated: Method GC/MS MATERIALS Total Results Results Positive Negative Materials Provided LSD Rapid Positive 79 1 80 LSD • Test device • Desiccants • Package insert • Urine cups Test Dip card Negative 1 99 100 Materials Required But Not Provided Total Results 80 100 180 One Step Lysergic acid diethylamide (LSD) Test Dip card (Urine) • Specimen collection container % Agreement 98.8% 99. % 98.9% • Timer Package Insert DIRECTIONS FOR USE Analytical Sensitivity This Instruction Sheet is for testing of Lysergic acid diethylamide. Allow the test device, and urine specimen to come to room temperature [15-30°C (59-86°F)] prior to testing. A drug-free urine pool was spiked with LSD at the following concentrations: 0 ng/mL, -50%cutoff, -25%cutoff, cutoff, A rapid, one step test for the qualitative detection of Lysergic acid diethylamide and its metabolites in human urine. 1) Remove the test device from the foil pouch. +25%cutoff and +50%cutoff. The result demonstrates >99% accuracy at 50% above and 50% below the cut-off For forensic use only. 2) Remove the cap from the test device. Label the device with patient or control identifications. concentration. The data are summarized below: INTENDED USE 3) Immerse the absorbent tip into the urine sample for 10-15 seconds. Urine sample should not touch the plastic Lysergic acid diethylamide (LSD) Percent of Visual Result The One Step Lysergic acid diethylamide (LSD) Test Dip card (Urine) is a lateral flow chromatographic device.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]
  • IV. CONTENTS of the 10Th EDITION
    EUROPEAN PHARMACOPOEIA 10.0 Contents of the 10th Edition IV. CONTENTS OF THE 10th EDITION The 10th Editionconsistsofnewtextsaswellasallcurrenttextsfromthe9th Edition, some of which have been revised or corrected. Lists of the monographs and general chapters that, for the 10th Edition, are new, revised or corrected, or have had their titles or chapter numbers changed, are given below. Theversiondate(forexample01/2020foratextthatisneworrevisedforthe10th Edition), completed by ‘corrected X.X’ if a corrected version of the text has subsequently been published in Supplement X.X, and the reference number (4 digits for monographs and 5 digits for general chapters) are specified above the title of each monograph and general chapter. The version date, completed by ‘corrected X.X’ if appropriate, makes it possible to identify the successive versions of texts in different editions. ThevolumeinwhichthecurrentversionwasfirstpublishedisstatedintheKnowledgedatabaseontheEDQMwebsite. As of the 10th Edition, all revised or corrected parts of a text are indicated by vertical lines in the margin and horizontal lines in themarginindicatewherepartsofatexthavebeendeleted.Linesinthemarginthatwerepresentinrevisedorcorrectedtexts in the previous edition are deleted with each new edition. Corrected texts are to be taken into account as soon as possible and not later than the end of the month following the month of publication of the volume. New and revised texts are to be taken into account not later than the implementation date. A barcode is included at the start of each text, providing a link to further information on the text (e.g. the Knowledge database) for smartphones and tablets with a camera and a barcode reader app. In addition to corrections made to individual texts, the following decisions and systematic modifications have been made to the texts of the European Pharmacopoeia for the 10th Edition.
    [Show full text]
  • Review Memorandum
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k112395 B. Purpose for Submission: New device C. Measurand: Phencyclidine and Nortriptyline D. Type of Test: Qualitative immunochromatographic E. Applicant: Guangzhou Wondfo Biotech Co., Ltd. F. Proprietary and Established Names: Wondfo Phencyclidine Urine Test Wondfo Nortriptyline Urine Test G. Regulatory Information: Product Classification Regulation Section Panel Code LCM unclassified Enzyme Immunoassay 91, Toxicology Phencyclidine LFG II 21 CFR 862.3910 -Tricyclic 91, Toxicology antidepressant drug test system H. Intended Use: 1. Intended use(s): See indication for use below 1 2. Indication(s) for use: Wondfo Phencyclidine Urine Test Wondfo Phencyclidine Urine Test is an immunochromatographic assay for the qualitative determination of Phencyclidine in human urine at a cutoff concentration of 25 ng/mL. The test is available in a dip card format and a cup format. It is intended for prescription use and over the counter use. The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. Wondfo Nortriptyline Urine Test Wondfo Nortriptyline Urine Test is an immunochromatographic assay for the qualitative determination of Nortriptyline (major metabolite of Tricyclic Antidepressants) in human urine at a cutoff concentration of 1000 ng/mL. The test is available in a dip card format and a cup format. It is intended for prescription use and over the counter use.
    [Show full text]
  • Intended Use Summary
    BARBITURATES (BAR) are central nervous system depressants. They are METHADONE METABOLITE (EDDP) is the primary metabolite of methadone. usually administered orally but are sometimes injected intramuscularly and Methadone is a synthetic analgesic drug that is originally used in the treatment intravenously. They range from short-acting (approximately 15 minutes, such of narcotic addicts. The detection of EDDP is more beneficial than traditional as secobarbital) to long-acting (24 hours or longer, such as phenobarbital). methadone screening since EDDP exists only in urine from individuals that Short-acting barbiturates are extensively metabolized in the body, while the ingested methadone. The tampering of specimens by spiking the urine with long-acting ones are secreted primarily unchanged. They produce alertness, methadone can be prevented. Secondly, renal clearance of EDDP is not wakefulness, increased energy, reduced hunger, and an overall feeling of well affected by urinary pH, therefore the EDDP test provides a more accurate being. Large doses of barbiturate could develop tolerance and physiological result of methadone ingestion than the methadone parent screen. dependency and lead to its abuse. METHYLENEDIOXYMETHAMPHETAMINE: ECSTASY (MDMA) belongs to a BENZODIAZEPINES (BZO) are a class of drugs that are often therapeutically family of man-made drugs. Relatives are MDA (methylenedioxyamphetamine) used as anxiolytics, anti-convulsants and sedative hypnotics. They manifest and MDEA (methylenedioxyethylamphetamine). All share amphetamine-like
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Toxicity and Residues of Oxolinic Acid
    /00)51 14) MIF111/41STIFIll Fn1autImit4 unniwinfhlvmm000ni/ISCIFI Toxicity and residues of oxolinic acid iht'inof 4'un1715.:4111 ?nevi lonthl,1035Qa Lutymut aunt] AffuTuiivEr uar, 1,5491-no11( litytmolairti Abstract: Peerasak Chantaraprateep, Palarp Sinhaseni, Venus Udomprasertgul, Benjaphorn Rungphitackchai, Somchai Issaravanich and Rerngsak Boonbundarichai. 1998. Toxicity and residues of oxolinic acid. Thai J Hlth Resch 12(2): 125 - 139. Oxolinic acid is a quinolone derivative. It is a synthetic antimicrobial agent which used to treat bacterial urinary tract infections, especially gram negative bacteria. It has been used in veterinary medicine for the control of furunculosis, vibriosis and enteric redmouth diseases. The mechanism of action of oxolinic acid inhibited bacterial DNA synthesis by effecting on bacterial DNA gyrase. Toxicity of oxolinic acid occured mainly to the central nervous system and gastrointestinal tract. Most of studies of residues of oxolinic acid were found in aquaculture animals such as fish and shrimp because oxolinic acid is used worldwide in aquaculture industry. The studies found that the absorption of oxolinic acid in rainbow trout depended on the temperature of water. And the residue time of oxytetracycline in sediment was longer than oxolinic acid. In addition, oxolinic acid in hepatopancreas of shrimp had more higher concentration than haemolymph and muscle and it also persisted in hepatopancreas longer than muscle. Key words : Toxicity, Residues, Oxolinic acid tnt711)9FAVITIKVOVf truvrirt; nI4LIVe1 10330. Institute of Health Research, Chulalong,korn University, Bangkok 10330. 126 ihrkg uatatut 715a1559nlrerwrlawitnstaniti urfroin: i15r.Xt-161 1410111 6,1141.11r.ta5st-la tufpnli4 d atIteltl 5alnifirzfri tilancit tIconlfriaiiii. 2541. frIltaildlit# illailliVirveisinanilttroni. 12(2): 125 - 139 .
    [Show full text]
  • ESVAC 8Th Report. Sales of Veterinary Antimicrobial Agents in 30
    Sales of veterinary antimicrobial agents in 30 European countries in 2016 Trends from 2010 to 2016 Eighth ESVAC report An agency of the European Union Mission statement The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role • involves representatives of patients, healthcare professionals and other stakeholders in its work, to facilitate dialogue on The European Medicines Agency (hereinafter ‘the Agency’ issues of common interest; or EMA) is the European Union (EU) body responsible for coordinating the existing scientific resources put at its disposal • publishes impartial and comprehensible information about by Member States for the evaluation, supervision and medicines and their use; pharmacovigilance of medicinal products. • develops best practice for medicines evaluation and The Agency provides the Member States and the institutions supervision in Europe, and contributes alongside the Member of the EU and the European Economic Area (EEA) countries States and the EC to the harmonisation of regulatory with the best-possible scientific advice on any questions standards at the international level. relating to the evaluation of the quality, safety and efficacy of medicinal products for human or veterinary use referred to it in accordance with the provisions of EU legislation Guiding principles relating to medicinal products. • We are strongly committed to public and animal health. The founding legislation of the Agency is Regulation (EC) No • We make independent recommendations based on scien- 726/2004 of the European Parliament and the Council of 31 tific evidence, using state-of-the-art knowledge and March 2004 laying down Community procedures for the expertise in our field.
    [Show full text]
  • Report Name:China Publishes Maximum Residue Limits for Veterinary Drugs in Food
    Voluntary Report – Voluntary - Public Distribution Date: December 11,2019 Report Number: CH2019-0176 Report Name: China Publishes Maximum Residue Limits for Veterinary Drugs in Food Country: China - Peoples Republic of Post: Beijing Report Category: FAIRS Subject Report Prepared By: Abraham Inouye Approved By: LASHONDA MCLEOD Report Highlights: On September 6, 2019, China issued a National Food Safety Standard on Maximum Residue Limits for Veterinary Drugs in Foods (GB 31650-2019), which will take effect on April 1, 2020. The standard replaces portions from Announcement No. 235 of the Ministry of Agriculture and Rural Affairs, published in December 2002. A draft version of this standard was notified to the WTO as G/SPS/N/CHN/1061 on December 18, 2017. This report contains an unofficial translation of the document. I (BEGIN TRANSLATION) National Food Safety Standard-Maximum Residue Limits for Veterinary Drugs in Foods GB-31650-2019 Issued on September 6, 2019 Implemented on April 1, 2020 Issued by the Ministry of Agriculture and Rural Affairs of China, the National Health Commission of China, and the State Administration of Market Regulation II Table of Contents Preface XI 1 Scope ........................................................................................................................12 2 Normative reference.................................................................................................12 3 Terms and definitions...............................................................................................12
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]